s6y

Champions Oncology, Inc.

Nasdaq
CSBR
CIK
771856
Industry
Biological Products, (No Diagnostic Substances)
Based in
Baltimore, Maryland
Incorporated in
Delaware
Fiscal year ends
April 30
SEC filer category
Non-accelerated filer, Smaller reporting company
Employer ID (EIN)
52-1401755
Formerly
Champions Biotechnology, Inc., Champions Sports Inc

Key figures

Fiscal year to Apr 2026 Apr 2025 Apr 2024 Apr 2023 Apr 2022
Revenue $59.4M$56.9M$50.2M$53.9M$49.1M
Operating income −$1.14M$4.55M−$7.36M−$5.26M$607.0K
Net income −$1.18M$4.70M−$7.28M−$5.33M$548.0K
Diluted EPS −$0.08$0.33−$0.54−$0.39$0.04
Cash from operations −$4.47M$7.39M−$6.14M$3.97M$6.50M
Total assets $27.0M$32.3M$26.1M$34.3M$35.4M
Shareholders’ equity $3.94M$3.77M−$1.90M$4.64M$9.10M

From the company’s annual reports to the SEC. Each year links to its report.

Financials 85

  1. 10-Q Quarterly Report for period ending Jul 31, 2026
  2. 10-K Annual Report for period ending Apr 30, 2026
  3. 10-Q Quarterly Report for period ending Jan 31, 2026
  4. 10-Q Quarterly Report for period ending Oct 31, 2025
  5. 10-Q Quarterly Report for period ending Jul 31, 2025
  6. 10-K Annual Report for period ending Apr 30, 2025
  7. 10-Q Quarterly Report for period ending Jan 31, 2025
  8. 10-Q Quarterly Report for period ending Oct 31, 2024
  9. 10-Q Quarterly Report for period ending Jul 31, 2024
  10. 10-K Annual Report for period ending Apr 30, 2024

All 85 financials filings

News 160

  1. 8-K Shareholder vote results
  2. 8-K Financial results
  3. 8-K Financial results
  4. 8-K Director or officer change
  5. 8-K Financial results
  6. 8-K Financial results
  7. 8-K Shareholder vote results
  8. 8-K Financial results
  9. 8-K Financial results
  10. 8-K Financial statements and exhibits

All 160 news filings

Ownership 271

  1. 4 Change in insider ownership
  2. 4 Change in insider ownership
  3. 4 Change in insider ownership
  4. 4 Ackerman Joel: Change in insider ownership
  5. 4 Ackerman Joel: Change in insider ownership
  6. 4 Change in insider ownership
  7. 4 Change in insider ownership
  8. 3 Initial statement of insider ownership
  9. 4 Change in insider ownership
  10. 4 Sidransky David: Change in insider ownership

All 271 ownership filings

Prospectus 8

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  3. S-1/A General form of registration statement for all companies including face-amount certificate companies
  4. S-1 General form of registration statement for all companies including face-amount certificate companies
  5. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  6. 424B3 Prospectus filed pursuant to Rule 424(b)(3)
  7. S-1 General form of registration statement for all companies including face-amount certificate companies
  8. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Proxies 36

  1. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  2. DEF 14A Definitive proxy statements
  3. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  4. DEF 14A Definitive proxy statements
  5. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  6. DEF 14A Definitive proxy statements
  7. DEFA14A Definitive additional proxy soliciting materials including Rule 14(a)(12) material. Note: Submission type DEFA14A can be filed as part of Form 8-K. For filers subject to 8-K filing requirements, we recommend the use of the 8-K combined form type as the easiest method for fulfilling your filing requirement for both forms.
  8. DEF 14A Definitive proxy statements
  9. DEF 14A Definitive proxy statements
  10. DEF 14A Definitive proxy statements

All 36 proxies filings

Other 99

  1. UPLOAD Letter (PDF)
  2. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  3. UPLOAD Letter (PDF)
  4. EFFECT Notice of Effectiveness
  5. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  6. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. UPLOAD Letter (PDF)
  9. EFFECT Notice of Effectiveness
  10. POS AM Post-effective amendment to a registration statement that is not immediately effective upon filing

All 99 other filings

Others in Biological Products, (No Diagnostic Substances)

Every company in this industry